Clinical features of unilateral acute idiopathic maculopathy identified

Article

According to a study in the Archives of Ophthalmology visual recovery of unilateral acute idiopathic maculopathy is linked with structural changes, suggesting that inflammation of the inner choroid, retinal pigment epithelium and partially reversible outer photoreceptor complex are involved in the cause of the disease.

According to a study in the Archives of Ophthalmology visual recovery of unilateral acute idiopathic maculopathy is linked with structural changes, suggesting that inflammation of the inner choroid, retinal pigment epithelium and partially reversible outer photoreceptor complex are involved in the cause of the disease.

A team led by Dr Cecilia S. Jung, Department of Vitreoretinal Surgery and Disease, Emory University, Atlanta, Georgia, USA, conducted a retrospective review on 4 unilateral acute idiopathic maculopathy patients. Clinical characteristics including age, symptoms, Snellen visual acuity and fundoscopic features were analysed. Images from spectral-domain optical coherence tomography (SD-OCT), fundus autofluorescence, fluorescein angiography and indocyanine green angiography were also evaluated.

Viral prodome, orchitis, hand-foot-mouth disease and positive coxsackievirus titers were among the associated findings present in the patients. Median visual acuity improved from 20/400 to 20/30 at follow-up, with a median follow-up time of 8 weeks.

The central macula developed irregular, circular white-grey areas of discolouration during the early stages of disease. SD-OCT presented with a partially reversible disruption of the outer photoreceptor layer.

Irregular early hyperfluorescence and late subretinal hyperfluorescence was identified with fluorescein angiography. Choroidal inflammation was found with indocyanine green angiography.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.